Erratum: Epigenomic characterization of a p53-regulated 3p22.2 tumor suppressor that inhibits STAT3 phosphorylation via protein docking and is frequently methylated in esophageal and other carcinomas: Erratum

Lili Li¹, Juan Xu^{1

2}, Guohua Qiu³, Jianming Ying^{1

4}, Zhenfang Du¹, Tingxiu Xiang⁵, Kai Yau Wong⁶, Gopesh Srivastava⁶, Xiao-Feng Zhu⁷, Tony S Mok¹, Anthony Tc Chan¹, Francis Kl Chan⁸, Richard F Ambinder^{3

9}, Qian Tao^{1

3

9}

Affiliations

¹ Cancer Epigenetics Laboratory, Department of Clinical Oncology, State Key Laboratory of Oncology in South China, Sir YK Pao Center for Cancer and Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong.
² Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen, China.
³ Johns Hopkins Singapore, Singapore.
⁴ Department of Pathology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
⁵ Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
⁶ Department of Pathology, Queen Mary Hospital, The University of Hong Kong.
⁷ State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China.
⁸ Institute of Digestive Disease and State Key Laboratory of Digestive Diseases, Department of Medicine and Therapeutics, The Chinese University of Hong Kong.
⁹ Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore.

Published Erratum

Lili Li et al. Theranostics. 2022.

. 2022 Jan 21;12(4):1736-1737.

doi: 10.7150/thno.70351. eCollection 2022.

¹ Cancer Epigenetics Laboratory, Department of Clinical Oncology, State Key Laboratory of Oncology in South China, Sir YK Pao Center for Cancer and Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong.
² Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen, China.
³ Johns Hopkins Singapore, Singapore.
⁴ Department of Pathology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
⁵ Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
⁶ Department of Pathology, Queen Mary Hospital, The University of Hong Kong.
⁷ State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China.
⁸ Institute of Digestive Disease and State Key Laboratory of Digestive Diseases, Department of Medicine and Therapeutics, The Chinese University of Hong Kong.
⁹ Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore.

Abstract

[This corrects the article DOI: 10.7150/thno.20893.].

Epigenomic characterization of a p53-regulated 3p22.2 tumor suppressor that inhibits STAT3 phosphorylation via protein docking and is frequently methylated in esophageal and other carcinomas.
Li L, Xu J, Qiu G, Ying J, Du Z, Xiang T, Wong KY, Srivastava G, Zhu XF, Mok TS, Chan AT, Chan FK, Ambinder RF, Tao Q. Li L, et al. Theranostics. 2018 Jan 1;8(1):61-77. doi: 10.7150/thno.20893. eCollection 2018. Theranostics. 2018. PMID: 29290793 Free PMC article.